IA
IOVA icon

IFG Advisory’s Iovance Biotherapeutics IOVA Stock Holding History

IFG Advisory’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$449 Buy
+108
New +$410 ﹤0.01% 2257

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

IFG Advisory's IOVA Position: Q2 2026 in Review

IFG Advisory opened a new position in Iovance Biotherapeutics (IOVA) in Q2 2026: 108 shares worth $449. The stake represents ﹤0.01% of the portfolio and ranks #2257 among its holdings.

292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • IFG Advisory held 108 shares of Iovance Biotherapeutics worth $449 as of Q2 2026.
  • Iovance Biotherapeutics was a new IFG Advisory position in Q2 2026.
  • Iovance Biotherapeutics made up ﹤0.01% of IFG Advisory's portfolio in Q2 2026, its #2257 holding.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on IFG Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.